ATNM STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Actinium Pharmaceuticals, Inc. and Encourages Shareholders to Contact the Firm!
NEW YORK, NY / ACCESSWIRE / August 14, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Actinium Pharmaceuticals, Inc. ("Actinium" or "the Company") (NYSE:ATNM). Investors who purchased Actinium securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ATNM.
Actinium Pharmaceuticals Inc Investors Urged To Participate In Fraud Investigation With The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 14, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Actinium Pharmaceuticals, Inc. ("Actinium" or "the Company") (NYSE American: ATNM ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
An Investigation Has Commenced on Behalf of Actinium Pharmaceuticals, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your ATNM Losses
NEW YORK, NY / ACCESSWIRE / August 13, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Actinium Pharmaceuticals, Inc. ("Actinium") (NYSE:ATNM) concerning possible violations of federal securities laws. Actinium issued a press release on August 5, 2024, "announc[ing] a regulatory update on the Company's planned Biologics License Application (‘BLA') filing for Iomab-B in patients with active relapsed or refractory acute myeloid leukemia (‘r/r AML').
ATNM SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Actinium Pharmaceuticals, Inc. and Encourages Shareholders to Contact the Firm!
NEW YORK, NY / ACCESSWIRE / August 13, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Actinium Pharmaceuticals, Inc. ("Actinium" or "the Company") (NYSE:ATNM). Investors who purchased Actinium securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ATNM.
Actinium Pharmaceuticals, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - ATNM
NEW YORK, NY / ACCESSWIRE / August 13, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Actinium Pharmaceuticals, Inc. ("Actinium") (NYSE:ATNM) concerning possible violations of federal securities laws. Actinium issued a press release on August 5, 2024, "announc[ing] a regulatory update on the Company's planned Biologics License Application (‘BLA') filing for Iomab-B in patients with active relapsed or refractory acute myeloid leukemia (‘r/r AML').
Investors Encouraged To Join The Actinium Pharmaceuticals Inc Fraud Investigation With The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 13, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Actinium Pharmaceuticals, Inc. ("Actinium" or "the Company") (NYSE American: ATNM ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Actinium Pharmaceuticals, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - ATNM
NEW YORK, NY / ACCESSWIRE / August 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Actinium Pharmaceuticals, Inc. ("Actinium") (NYSE:ATNM) concerning possible violations of federal securities laws. Actinium issued a press release on August 5, 2024, "announc[ing] a regulatory update on the Company's planned Biologics License Application (‘BLA') filing for Iomab-B in patients with active relapsed or refractory acute myeloid leukemia (‘r/r AML').
ATNM INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Actinium Pharmaceuticals, Inc. and Encourages Shareholders to Contact the Firm!
NEW YORK, NY / ACCESSWIRE / August 12, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Actinium Pharmaceuticals, Inc. ("Actinium" or "the Company") (NYSE:ATNM). Investors who purchased Actinium securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ATNM.
Did Actinium Pharmaceuticals, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - ATNM
NEW YORK, NY / ACCESSWIRE / August 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Actinium Pharmaceuticals, Inc. ("Actinium") (NYSE:ATNM) concerning possible violations of federal securities laws. Actinium issued a press release on August 5, 2024, "announc[ing] a regulatory update on the Company's planned Biologics License Application (‘BLA') filing for Iomab-B in patients with active relapsed or refractory acute myeloid leukemia (‘r/r AML').
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Actinium Pharmaceuticals, Inc. - ATNM
NEW YORK, NY / ACCESSWIRE / August 11, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") (NYSE:ATNM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
ATNM STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Actinium Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm!
NEW YORK, NY / ACCESSWIRE / August 11, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Actinium Pharmaceuticals, Inc. ("Actinium" or "the Company") (NYSE:ATNM). Investors who purchased Actinium securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ATNM.
Actinium Pharmaceuticals, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - ATNM
NEW YORK, NY / ACCESSWIRE / August 9, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Actinium Pharmaceuticals, Inc. ("Actinium") (NYSE:ATNM) concerning possible violations of federal securities laws. Actinium issued a press release on August 5, 2024, "announc[ing] a regulatory update on the Company's planned Biologics License Application (‘BLA') filing for Iomab-B in patients with active relapsed or refractory acute myeloid leukemia (‘r/r AML').
